TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30857431

Group type: EXPERIMENTAL
Intervention: Targeted, personalized risk information intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 0
Study: 30051368

Group type: EXPERIMENTAL
Intervention: Tumor location-modified Lauren classification (mLC)
Number of subjects: 2764

Group type: COMPARATOR
Intervention: Lauren classification (LC)
Number of subjects: 2764

Group type: EXPERIMENTAL
Intervention: Nomogram based on mLC
Number of subjects: 2764
Study: 26004421

Group type: EXPERIMENTAL
Intervention: CIRCuiTS (Computerized Cognitive Remediation Therapy Programme)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: CIRCuiTS
Number of subjects: 59
Study: 24164640

Group type: EXPERIMENTAL
Intervention: Doppler echocardiography (DE) and three-dimensional echocardiography (3DE) for AV- and VV-interval optimization (group 1, n = 39)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Conventional electrocardiogram (ECG) optimization (group 2, n = 38)
Number of subjects: 77
Study: 22759830

Group type: EXPERIMENTAL
Intervention: Autologous platelet-rich plasma eyedrops along with standard medical treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard medical treatment alone
Number of subjects: 20
Study: 20096936

Group type: EXPERIMENTAL
Intervention: Asenapine (10mg BID on day 1, 5 or 10mg BID thereafter)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Olanzapine (15 mg QD on day 1, 5-20mg QD thereafter)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Asenapine
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 185
Study: 18703470

Group type: EXPERIMENTAL
Intervention: PCI plus optimal medical therapy
Number of subjects: 2287

Group type: COMPARATOR
Intervention: Optimal medical therapy alone
Number of subjects: 2287

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 2287
Study: 15658966

Group type: EXPERIMENTAL
Intervention: Webster-Stratton Parenting Programme
Number of subjects: 0
Study: 12558710

Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) rehydration
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) rehydration
Number of subjects: 96

Group type: COMPARATOR
Intervention: IV/SC subgroup (patients who changed from IV to SC)
Number of subjects: 96

Group type: COMPARATOR
Intervention: SC/IV subgroup (patients who changed from SC to IV)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Both SC and IV methods
Number of subjects: 96
Study: 10677386

Group type: EXPERIMENTAL
Intervention: C-peptide infusion at 3 pmol.min(‐1).kg(‐1) for 60 min and then at 10 pmol.min(‐1).kg(‐1) for 60 min
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: C-peptide infusion
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 10
Study: 8931848

Group type: EXPERIMENTAL
Intervention: Bunazosin retard (12 mg)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Prazosin retard (4 mg)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study: 1415970

Group type: EXPERIMENTAL
Intervention: Repeated neutral phrases including the colour orange
Number of subjects: 80

Group type: COMPARATOR
Intervention: Repeated neutral phrases including the colour green
Number of subjects: 80
Study: 3893286

Group type: EXPERIMENTAL
Intervention: Local treatment plus thymostimulin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Local treatment plus placebo (control group)
Number of subjects: 30
Study: 31388739

Group type: EXPERIMENTAL
Intervention: Spirulina (4.8 g daily for 17 days)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Wakame (4.8 g daily for 17 days)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 29317001

Group type: EXPERIMENTAL
Intervention: Video-Based Learning (VBL)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Traditional Lecture (TL)
Number of subjects: 26
Study: 28002316

Group type: EXPERIMENTAL
Intervention: Oral pregabalin 150 mg and intravenous normal saline (group HP)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine 40 mg (group L)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Oral pregabalin 75 mg and intravenous normal saline (group LP)
Number of subjects: 120
Study: 24231639

Group type: EXPERIMENTAL
Intervention: High protein intake (≥ 4.6 g · kg(‐1) · day(‐1))
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Average protein intake of 4.3 ± 0.4 g · kg(‐1) · day(‐1)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: High protein group (4.6 to 5.5 g · kg(‐1) · day(‐1), n = 16)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Cumulative total kilocalories and protein
Number of subjects: 56
Study: 23326930

Group type: EXPERIMENTAL
Intervention: Test treatment (nutriological combination of vitamins, trace elements, and phytochemicals)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Test treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 20615100

Group type: EXPERIMENTAL
Intervention: GLIM + PIO combination (up-titration 2 mg + 30 mg/4 mg + 30 mg/4 mg + 4 mg)
Number of subjects: 82

Group type: COMPARATOR
Intervention: GLIM (up-titration 4/5/6 mg)
Number of subjects: 82
Study: 18341414

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 40
Study: 15723969

Group type: EXPERIMENTAL
Intervention: Candesartan (8 to 16 mg per day)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Enalapril (10 to 20 mg per day)
Number of subjects: 15
Study: 12689739

Group type: COMPARATOR
Intervention: Paper diary
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Electronic diary with compliance-enhancing features
Number of subjects: 0
Study: 12870993

Group type: EXPERIMENTAL
Intervention: DHE focused on diet
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: DHE focused on oral hygiene instruction (OHI) using fluoride toothpaste
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: DHE by a combined diet and OHI message
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: DHE given once a year
Number of subjects: 228

Group type: COMPARATOR
Intervention: Control group (E) with no DHE
Number of subjects: 228
Study: 9690309

Group type: EXPERIMENTAL
Intervention: Chemotherapy containing platinum
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemotherapy using alkylating agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemotherapy with Cisplatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Concomitant radiotherapy and chemotherapy using 5-Fluoro-uracil, VP16, and platinum
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short initial chemotherapy or concomitant therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short neoadjuvant chemotherapy to surgery
Number of subjects: 0
Study: 7853038

Group type: EXPERIMENTAL
Intervention: Meta-analytic methods for diagnostic test accuracy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moses et al. method for estimating Summary Receiver Operating Characteristic Curves
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methods for analysing multi-category and continuous test data
Number of subjects: 0
Study: 2345633

Group type: EXPERIMENTAL
Intervention: Silymarin (Legalon) therapy at a daily dose of 420 mg for six months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study: 378199

Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 6303490

Group type: EXPERIMENTAL
Intervention: Ceftriaxone 250 mg intramuscularly
Number of subjects: 128

Group type: COMPARATOR
Intervention: Cefoxitin 2 g intramuscularly with oral probenecid 1 g
Number of subjects: 128
Study: 26803355

Group type: EXPERIMENTAL
Intervention: Exenatide supplementation on glargine insulin (group B)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Intense, self-regulated insulin therapy alone (group C)
Number of subjects: 110
Study: 25539976

Group type: EXPERIMENTAL
Intervention: Structured transition approach integrating Berliner TransitionsProgramm and two smartphone apps
Number of subjects: 17

Group type: COMPARATOR
Intervention: Current unstructured transition (control group)
Number of subjects: 17
Study: 22080870

Group type: EXPERIMENTAL
Intervention: Metacognitive therapy (MCT), 8 weekly intervention sessions
Number of subjects: 20

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 20
Study: 20411995

Group type: EXPERIMENTAL
Intervention: Pharmacists provided intensified hypertension management and drug adherence counseling
Number of subjects: 584

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 584
Study: 18684259

Group type: EXPERIMENTAL
Intervention: SVC On
Number of subjects: 42

Group type: COMPARATOR
Intervention: SVC Off
Number of subjects: 42

Group type: COMPARATOR
Intervention: SVC On and Off
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Best SVC configuration or deliberate PD programming
Number of subjects: 42
Study: 15966377

Group type: EXPERIMENTAL
Intervention: Epidural tramadol infusion
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intravenous tramadol infusion
Number of subjects: 20
Study: 12651051

Group type: EXPERIMENTAL
Intervention: Acute hyperglycemia (13.9 mmol/l, 250 mg/dl)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Euglycemia (5.5 mmol/l, 100 mg/dl)
Number of subjects: 12
Study: 10824717

Group type: EXPERIMENTAL
Intervention: Acarbose (100 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 10
Study: 8862500

Group type: EXPERIMENTAL
Intervention: Postmenopausal women
Number of subjects: 41

Group type: COMPARATOR
Intervention: Premenopausal women
Number of subjects: 41
Study: 1436561

Group type: EXPERIMENTAL
Intervention: General balanced anaesthesia
Number of subjects: 17

Group type: COMPARATOR
Intervention: Spinal anaesthesia
Number of subjects: 17
Study: 6323866

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Bromocriptine (CB-154)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Basal conditions (control)
Number of subjects: 4
Study: 31491932

Group type: EXPERIMENTAL
Intervention: Exercise + Learning (E + L)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Learning Only (L)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Exercise Only (E)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control Group (C)
Number of subjects: 80
Study: 29174765

Group type: EXPERIMENTAL
Intervention: Attention Control Treatment (ACT)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Attention Bias Modification Treatment (ABMT)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Both ACT and ABMT
Number of subjects: 46
Study: 26638192

Group type: EXPERIMENTAL
Intervention: Low-Fat Diet (LF)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Low-Carbohydrate Diet (LC)
Number of subjects: 61
Study: 24668700

Group type: EXPERIMENTAL
Intervention: Flavonoids (Group A)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (Group B)
Number of subjects: 24
Study: 22607043

Group type: EXPERIMENTAL
Intervention: V(10)-group (10% of ED(95) vecuronium)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: V(15)-group (15% of ED(95) vecuronium)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: V(20)-group (20% of ED(95) vecuronium)
Number of subjects: 100

Group type: COMPARATOR
Intervention: V(0)-group (no priming)
Number of subjects: 100
Study: 20513268

Group type: EXPERIMENTAL
Intervention: Intervention Schools (IS) - nutrition education and improvement of the food environment
Number of subjects: 659

Group type: COMPARATOR
Intervention: Control Schools (CS)
Number of subjects: 659
Study: 18407341

Group type: EXPERIMENTAL
Intervention: Carboplatin (based on AUC of 7.5 and GFR from Jelliffe formula)
Number of subjects: 387
Study: 15760685

Group type: EXPERIMENTAL
Intervention: Intracardiac echocardiography (ICE)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Transesophageal echocardiography (TEE)
Number of subjects: 80
Study: 12446070

Group type: EXPERIMENTAL
Intervention: CMR-determined graft flow and flow reserve
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Algorithm combining basal volume flow <20 ml/min and graft flow reserve <2
Number of subjects: 21
Study: 10100178

Group type: EXPERIMENTAL
Intervention: High dose E2/NETA (2 mg E2/1 mg NETA)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Low dose E2/NETA (1 mg E2/0.5 mg NETA)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 54
Study: 8889353

Group type: EXPERIMENTAL
Intervention: Usual MAP goal group (102-107 mm Hg)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Low MAP goal group (<= 92 mm Hg)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Enalapril drug regimen
Number of subjects: 94

Group type: COMPARATOR
Intervention: Atenolol drug regimen
Number of subjects: 94

Group type: COMPARATOR
Intervention: Amlodipine drug regimen
Number of subjects: 94
Study: 1905631

Group type: EXPERIMENTAL
Intervention: Diet rich in polyunsaturated fat (10% saturated fat, 9% monounsaturated fat, 18% polyunsaturated fat)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Diet rich in saturated fat (21% saturated fat, 12% monounsaturated fat, 3% polyunsaturated fat)
Number of subjects: 12
Study: 7104149

Group type: EXPERIMENTAL
Intervention: metoprolol, 100-300 mg/day
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: pindolol, 5-15 mg/day
Number of subjects: 36
Study: 30499837

Group type: EXPERIMENTAL
Intervention: Group MP (300 mg pregabalin orally + IV magnesium sulphate 50 mg/kg)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Group P (300 mg pregabalin orally + IV placebo)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Group M (IV magnesium sulphate 50 mg/kg + placebo capsule)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Group C (placebo capsule + IV placebo)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Group MP, P, M
Number of subjects: 120
Study: 30650288

Group type: EXPERIMENTAL
Intervention: Xinfeng Capsule (XFC), 3 pills each time, 3 times per day for 3 months
Number of subjects: 70

Group type: COMPARATOR
Intervention: Glucosamine, 1 pill each time, 3 times per day for 3 months
Number of subjects: 70
Study: 26703477

Group type: EXPERIMENTAL
Intervention: Intra-articular facet joint injections with local anaesthetic and steroids
Number of subjects: 150

Group type: COMPARATOR
Intervention: Best usual care package with physical and psychological components
Number of subjects: 150
Study: 24303967

Group type: EXPERIMENTAL
Intervention: Atypical P-wave morphology
Number of subjects: 892
Study: 20022553

Group type: EXPERIMENTAL
Intervention: ZengShengPing (ZSP) - 4 tablets, 3 times per day for 8-12 months
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: ZengShengPing (ZSP) - 6g/kgBW/day by gavage for 10 weeks
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: ZengShengPing (ZSP) - 10% in diet
Number of subjects: 59
Study: 18154900

Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (head cooling for 72 hours starting within 6 hours of birth, rectal temperature maintained at 34.5 degrees C ± 0.5 degrees C)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Standard care (maintained at 37.0 degrees C ± 0.5 degrees C)
Number of subjects: 234
Study: 16279916

Group type: COMPARATOR
Intervention: Milk thistle (MT)
Number of subjects: 915
Study: 12850615

Group type: EXPERIMENTAL
Intervention: Immediate pushing (n = 85)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Delayed pushing (n = 117)
Number of subjects: 202
Study: 10531164

Group type: EXPERIMENTAL
Intervention: Mode 1 (pressure variation from 4 to 15.5 cm H(2)O)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Mode 2 (pressure variation from 4 cm H(2)O to individual upper limit)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Manual titrated nCPAP therapy
Number of subjects: 11
Study: 8905934

Group type: EXPERIMENTAL
Intervention: Zopiclone
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Nitrazepam
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study: 1989572

Group type: EXPERIMENTAL
Intervention: 10 mg/d of oral haloperidol
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: 30 mg/d of oral haloperidol
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: 80 mg/d of oral haloperidol
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 87
Study: 6636033

Group type: EXPERIMENTAL
Intervention: 10 g of fish oil (n-3 PUFA) for 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: 10 g of vegetable oil (n-6 PUFA) for 4 weeks
Number of subjects: 0
Study: 30399034

Group type: EXPERIMENTAL
Intervention: CrAg screening and preemptive fluconazole therapy
Number of subjects: 3388
Study: 30555398

Group type: EXPERIMENTAL
Intervention: Self-help book for insomnia (cognitive behavioral therapy for insomnia)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Sleep hygiene advice
Number of subjects: 164
Study: 25228440

Group type: EXPERIMENTAL
Intervention: 10 mg lutein
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: 20 mg lutein
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: lutein (10 mg) + zeaxanthin (10 mg)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study: 22466015

Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery (MIS group)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Conventional surgery (CON group)
Number of subjects: 300
Study: 21316156

Group type: EXPERIMENTAL
Intervention: Waterpipe (WP)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Cigarettes
Number of subjects: 61
Study: 19043656

Group type: EXPERIMENTAL
Intervention: Alendronate therapy (with calcium 500 mg/day and cholecalciferol 250 IU/day)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Placebo (50% of participants)
Number of subjects: 1000
Study: 17868862

Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mepolizumab
Number of subjects: 0
Study: 14718892

Group type: EXPERIMENTAL
Intervention: Endovascular abdominal aortic aneurysm repair (EVAR)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Open repair (OR)
Number of subjects: 153
Study: 11259687

Group type: COMPARATOR
Intervention: Statin drugs (HMG CoA reductase inhibitors)
Number of subjects: 46340
Study: 9693477

Group type: EXPERIMENTAL
Intervention: Analyzing and reframing fashion advertisements (Intervention group)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Comparison group (Control group)
Number of subjects: 105
Study: 8848888

Group type: EXPERIMENTAL
Intervention: Spinal Anaesthesia (SA)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Epidural Anaesthesia (EA)
Number of subjects: 202
Study: 1977438

Group type: EXPERIMENTAL
Intervention: Cicloprolol 50 mg day‐1 with digoxin 0.25 mg day‐1
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo with digoxin 0.25 mg day‐1
Number of subjects: 10
Study: 318680

Group type: EXPERIMENTAL
Intervention: Dextroamphetamine (15 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Methylphenidate (20 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: L-dopa (125 to 500 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dextroamphetamine (after treatment with methylphenidate)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Methylphenidate (after treatment)
Number of subjects: 20
Study: 30999963

Group type: EXPERIMENTAL
Intervention: Vital signs triage intervention
Number of subjects: 2747
Study: 23453011

Group type: EXPERIMENTAL
Intervention: Intensive glycemic control (target blood glucose 120-160 mg/dl)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Control group (target blood glucose 161-200 mg/dl)
Number of subjects: 212
Study: 21557031

Group type: EXPERIMENTAL
Intervention: Quality of primary care measured by provision of eight recommended preventive services
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Panel Medicaid eligibility
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Delivery of influenza vaccine
Number of subjects: 0
Study: 19234885

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg twice daily for 3 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 16519632

Group type: EXPERIMENTAL
Intervention: Marsupialization (M group)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Open wound (O group)
Number of subjects: 46
Study: 12742557

Group type: EXPERIMENTAL
Intervention: Low-dose COC (20 microg EE and 75 microg GTD) - Group A
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Ultra-low-dose COC (15 microg EE and 60 microg GTD) - Group B
Number of subjects: 56

Group type: COMPARATOR
Intervention: Untreated controls - Group C
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: All groups (A, B, and C)
Number of subjects: 56
Study: 10945963

Group type: EXPERIMENTAL
Intervention: ATLS group
Number of subjects: 32

Group type: COMPARATOR
Intervention: Non-ATLS group
Number of subjects: 32
Study: 8922571

Group type: EXPERIMENTAL
Intervention: Azithromycin 10 mg/kg 1 x daily for 3 days
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Azithromycin 20 mg/kg 1 x daily for 3 days
Number of subjects: 489

Group type: COMPARATOR
Intervention: Penicillin V 125-250 mg 4 x daily for 10 days
Number of subjects: 489
Study: 1375807

Group type: EXPERIMENTAL
Intervention: Home visitation by nurses during pregnancy and continuing through at least the second year of the child's life
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Home visitation programs that meet certain standards
Number of subjects: 0
Study: 6690193

Group type: EXPERIMENTAL
Intervention: 111In‐labelled heat damaged autologous erythrocytes (HD‐RBC)
Number of subjects: 26

Group type: COMPARATOR
Intervention: 99mTc‐labelled erythrocytes (IgG‐RBC) coated with Rhesus anti‐D antibody (high coating)
Number of subjects: 26

Group type: COMPARATOR
Intervention: 99mTc‐labelled erythrocytes (IgG‐RBC) coated with Rhesus anti‐D antibody (low coating)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: HD‐RBC
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Indium labelled platelets
Number of subjects: 26
Study: 31706286

Group type: EXPERIMENTAL
Intervention: Herbal combination (420 mg proprietary blend of Urox®)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80